Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.
Asem ShalabyHeba A MahmoudShayma G SayedKhalid Al HashmiShadia Al-SinawiSuad Al BadiAfrah Al RashdiSamya Al HusainiHajer Al BadiSomaia Ahmed Saad El-DinPublished in: Asian Pacific journal of cancer prevention : APJCP (2024)
EGFR and HER2/neu may play a limited role in prostatic adenocarcinoma as they showed positive expression in a limited number of the examined tissues specifically HER2neu. The expression of non-phosphorylated ERK (mostly weak to moderate) and phosphorylated ERK (mostly moderate to strong)- was appreciated in most cases. Thus, we suggest that anti-EGFR drugs may have a limited role in the treatment of castrate-resistant prostate cancer, but anti-MEK/ERK drugs may have more promising role as a target therapy. It is recommended to perform further molecular testing to elucidate the exact mechanism and significance of these markers.
Keyphrases
- prostate cancer
- signaling pathway
- poor prognosis
- small cell lung cancer
- pi k akt
- epidermal growth factor receptor
- cell proliferation
- tyrosine kinase
- radical prostatectomy
- gene expression
- stem cells
- binding protein
- long non coding rna
- radiation therapy
- locally advanced
- rectal cancer
- drug induced
- single molecule
- density functional theory
- combination therapy